First-Line Pharmacologic Treatment for Teen Depression and Anxiety
SSRIs (Selective Serotonin Reuptake Inhibitors) are the first-line pharmacologic treatment for both depression and anxiety in adolescents, with fluoxetine having the strongest evidence base for depression and sertraline, fluoxetine, fluvoxamine, and escitalopram all supported for anxiety. 1, 2, 3
Depression Treatment
Medication Selection
For adolescent depression, fluoxetine is the gold standard with the most robust evidence and FDA approval for use in children and adolescents with depression 2. Escitalopram is FDA-approved for adolescents 12 years and older 2.
Recommended SSRI dosing for depression 2:
- Fluoxetine: Start 10 mg daily, increase by 10-20 mg increments, effective dose 20 mg, maximum 60 mg
- Escitalopram: Start 10 mg daily, increase by 5 mg increments, effective dose 10 mg, maximum 20 mg
- Sertraline: Start 25 mg daily, increase by 12.5-25 mg increments, effective dose 50 mg, maximum 200 mg
- Citalopram: Start 10 mg daily, increase by 10 mg increments, effective dose 20 mg, maximum 60 mg
Paroxetine is not recommended to be started in primary care due to tolerability concerns 2.
Evidence Base
The Treatment of Adolescent Depression Study demonstrated that fluoxetine alone or combined with CBT produced significantly greater improvement than placebo or CBT alone 2. Response rates to antidepressants range from 47-69% versus 33-57% for placebo, with the benefit-to-harm ratio favoring treatment 6:1 2.
Anxiety Treatment
Medication Selection
For adolescent anxiety disorders, the SSRI class as a whole has substantial empirical support, though no specific SSRIs have FDA approval for anxiety indications 1. The evidence supports fluoxetine, fluvoxamine, paroxetine, and sertraline 1.
Key dosing principles for anxiety 1:
- Start low and titrate slowly to avoid behavioral activation
- Most SSRIs permit once-daily dosing due to long half-lives
- Sertraline at low doses and fluvoxamine at any dose may require twice-daily dosing
- Clinical improvement typically occurs by week 6, with maximal benefit by week 12 or later
SNRIs as Second-Line
Serotonin-norepinephrine reuptake inhibitors (SNRIs) have some empirical support as an additional treatment option for anxiety 1, though they are generally less well-tolerated than SSRIs 2.
Critical Safety Monitoring
Black Box Warning
All SSRIs carry an FDA black box warning for suicidal thinking and behavior through age 24 1, 2. The absolute risk is 1% with antidepressants versus 0.2% with placebo (NNH = 143 versus NNT = 3 for response) 1.
Monitoring Schedule
Assess patients within 1 week of treatment initiation, then regularly throughout the first months of treatment and after any dose changes 2. Monitor can be in-person or by telephone 2.
At each contact, assess 2:
- Ongoing depressive/anxiety symptoms
- Suicidal ideation or behavior
- Adverse effects (use specific checklists)
- Treatment adherence
- New or ongoing stressors
Common Adverse Effects
Early-emerging (first few weeks) 1, 4:
- Gastrointestinal: nausea, diarrhea, abdominal pain (often transient)
- Activation: restlessness, insomnia, agitation (more common in younger children)
- Headache, dizziness, dry mouth
Late-emerging 4:
- Weight changes
- Sexual dysfunction (in adolescents)
Behavioral activation occurs more commonly in younger children and anxiety disorders, typically in the first month or with dose increases. It usually resolves quickly with dose reduction, unlike true mania which may persist 1.
Starting Safely
Never start at high doses—this increases risk of deliberate self-harm and suicidality 2. Use the recommended starting doses above and titrate slowly based on response and tolerability.
Treatment Duration
Continue medication for at least 1 year after response to prevent relapse 2. The greatest relapse risk occurs in the first 8-12 weeks after discontinuation 2. When discontinuing, taper slowly to avoid withdrawal effects 2, 4.
Combination Therapy
Combining an SSRI with CBT produces superior outcomes to either treatment alone for both depression and anxiety 2, 5. This approach is particularly effective for:
- Moderate to severe presentations
- Insufficient response to monotherapy
- More rapid symptom improvement needed
For depression, CBT or interpersonal therapy (IPT) plus fluoxetine is most effective 5. For anxiety, CBT plus sertraline shows the strongest evidence 5.
Medications to Avoid
Do not use 2:
- Tricyclic antidepressants (no demonstrated efficacy in adolescents)
- Benzodiazepines (no RCT evidence of efficacy in pediatric anxiety) 3
- Buspirone (no demonstrated efficacy) 3
Duloxetine and venlafaxine are among the most intolerable antidepressants in adolescents 2.